Concepedia

Evelyn McKeegan

EM

30

Publications

4.2K

Citations

23

H-Index

1989

Active since

Affiliations

Abbott Fund(Current)

AbbVie (United States)

Abbott (United Kingdom)

Dana-Farber Cancer Institute

The University of Texas MD Anderson Cancer Center

Evelyn McKeegan is an author at Abbott Fund specializing in medicine, oncology, and pharmacology.

Top concepts

Publications per year

1989–2016

30

Publications

30

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

Marina Konopleva, Daniel A. Pollyea, Jalaja Potluri et al. · Cancer Discovery · 2016 · 1K citations · Full text

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

Andrew W. Roberts, John F. Seymour, Jennifer R. Brown et al. · Journal of Clinical Oncology · 2011 · 808 citations · Full text

Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors

Leena Gandhi, D. Ross Camidge, Moacyr Oliveira et al. · Journal of Clinical Oncology · 2011 · 579 citations · Full text

Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

Charles M. Rudin, Christine L. Hann, Edward B. Garon et al. · Clinical Cancer Research · 2012 · 542 citations · Full text

Phase 2 trial of linifanib (ABT‐869) in patients with unresectable or metastatic hepatocellular carcinoma

Han Chong Toh, Pei‐Jer Chen, Brian I. Carr et al. · Cancer · 2012 · 106 citations · Full text

Rows per page

1–5 of 30